BG
EWTX icon

Bellevue Group’s Edgewise Therapeutics EWTX Stock Holding History

Bellevue Group’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,528,518
Closed -$48.1M – 158
2026
Q1 		$48.1M Hold
1,528,518
– – 1.15% 31
2025
Q4 		$37.9M Sell
1,528,518
-1,247,479
-45% -$25M 0.72% 32
2025
Q3 		$45M Hold
2,775,997
– – 0.94% 28
2025
Q2 		$36.4M Buy
2,775,997
+1,347,068
+94% +$19.4M 0.8% 33
2025
Q1 		$31.4M Hold
1,428,929
– – 0.7% 35
2024
Q4 		$38.2M Hold
1,428,929
– – 0.73% 29
2024
Q3 		$38.1M Hold
1,428,929
– – 0.62% 46
2024
Q2 		$25.7M Buy
+1,428,929
New +$24.9M 0.42% 62

Other funds holding EWTX

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Bellevue Group's EWTX Position: Q2 2026 in Review

Bellevue Group sold out of Edgewise Therapeutics (EWTX) in Q2 2026, closing a stake of 1,528,518 shares — an estimated $48.1M sold.

Bellevue Group first reported a position in EWTX in Q2 2024 and held it in 8 quarters. The position peaked at $48.1M in Q1 2026. 225 funds tracked by Wall St. Rank hold EWTX as of Q2 2026.

  • Bellevue Group reported no remaining Edgewise Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Bellevue Group sold 1,528,518 Edgewise Therapeutics shares in Q2 2026, an estimated $48.1M.
  • Bellevue Group first reported a position in Edgewise Therapeutics in Q2 2024 and held it in 8 quarters.
  • Bellevue Group's Edgewise Therapeutics position peaked at $48.1M in Q1 2026.
  • 225 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q2 2026.

Based on Bellevue Group's 13F filing for Q2 2026, filed 14 Aug 2026.